UroAlert - GU Oncology Weekly

January 22, 2026

Videos

Peer-to-Peer Clinical Conversations

Navigating Treatment Options and Trial Designs for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Vignesh Packiam

Vignesh Packiam

Vignesh Packiam outlines emerging intermediate-risk NMIBC trials from SUO 2025.

KEYMAKER-U03 Substudy Compares Four Combinations to Standard Therapy - Cristina Suárez

Cristina Suárez

Pedro Barata speaks with Cristina Suárez about KEYMAKER-U03 substudy 03A results evaluating checkpoint combinations in first-line metastatic clear cell renal cell carcinoma.

Beyond the Abstracts

Unraveling Smooth Muscle-Rich Renal Cell Carcinoma: Clinical, Oncological, Genetic, and Pathological Insights - Beyond the Abstract

Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer - Beyond the Abstract

Conference Coverage

SUO 2025: EAU Lecture: Active Surveillance of Renal Tumors: A 20-year Journey

SUO 2025: Heterogeneity in Early Postoperative Recovery Trajectories after Radical Cystectomy: Preliminary Findings from the Prospective University of Washington Bounceback Cohort Study

SUO 2025: ENLIGHTED Phase 3 Study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment ofLow-grade Upper Tract Urothelial Cancer (LG UTUC)

ESMO 2025: The Impact of Lead-in Androgen Deprivation Therapy on Severe Neutropenia (Grade≥3) Caused by Docetaxel in Patients with Metastatic, Hormone-sensitive Prostate Cancer (mHSPC): A Post Hoc Analysis of ARASENS

ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Intratumoral and Peritumoral Fat CT‑Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.

Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.

Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract.

Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.

Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification.

Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.

Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.

Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.

Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice.

Microbiome-linked transcriptomic signatures in NMIBC: Toward personalized uro-oncology.

Morbi-mortality of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.

Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.

A multi-modal approach for decision making in bladder cancer.

Development and External Validation of a Local Pelvic Recurrence Risk Score After Radical Cystectomy: Identifying the Ideal Candidate for Adjuvant Radiation Clinical Trials

Beyond Sterility: the Urinary Microbiome in Bladder Cancer Carcinogenesis and Treatment.

Safety of Transurethral Resection of Bladder Tumor in Octogenarians: A NSQIP Analysis - Beyond the Abstract

Penile & Urethral Cancers

Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility.

Spectrum of Human Papillomavirus (HPV)-Related Penile Cancer.

Renal Cancer

Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Treatment preferences of patients and physicians for early-stage and adjuvant treatment of urothelial carcinoma and renal cell carcinoma in Asia-Pacific: a discrete choice experiment.

Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.

Perioperative outcomes after Robot-assisted partial nephrectomy for very small (≤ 2 cm) versus larger small (> 2-4 cm) renal tumors: a multi-institutional propensity score-matched study.

Response assessment of patients with locally advanced renal cell carcinoma receiving prior systemic therapy.

LASER: A Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for RCC.

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials.

Long-term outcomes after cytoreductive partial nephrectomy for metastatic renal cell carcinoma.

Lesion distribution and prognosis of renal cell carcinoma bone metastasis: A novel evaluation model based on random survival forests.

An update on the treatment paradigm for non-clear cell renal cell carcinoma.

Mapping Heterogeneity in the Tumor Microenvironment of Renal Cell Carcinoma Through Single-Cell Omics - Beyond the Abstract

Unraveling Smooth Muscle-Rich Renal Cell Carcinoma: Clinical, Oncological, Genetic, and Pathological Insights - Beyond the Abstract

Nivolumab plus Ipilimumab Induce Hyper-Progression in Renal Medullary Carcinoma: How a “Negative” Trial May Save Lives - Beyond the Abstract

Prostate Cancer

Toward a PSMA PET-mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trial.

Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer.

Prostate Cancer Incidence by Age and Clinicopathological Characteristics: A Population-Based Study in Girona, Spain, 2010 to 2021.

Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer.

The KIM real-time prostate cancer IGRT technology journey: From clinical trials to your clinic.

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.

Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study.

MRI prostate tumor volume predicts the need for systematic biopsies in patients undergoing MRI-targeted biopsy.

Real-world Inter-rater Agreement of PI-QUAL Version 2 for Prostate Magnetic Resonance Imaging Quality Assessment and Its Association with Diagnostic Accuracy.

Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide.

Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates.

Inflammation and insulin profiles in men assigned to exercise vs. usual care for prostate cancer: results from the active surveillance exercise (ASX) randomized controlled trial.

Circulating tumour cells as a window into lethality in prostate cancer.

Long-term outcomes of Stereotactic MRI-guided adaptive radiotherapy (SMART) for prostate cancer: Results from a real world large patient cohort.

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

The role of multimodality imaging in selection, response assessment, and follow-up of patients receiving 177Lutetium-PSMA-therapy.

Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.

Predictive factors for negative prostate biopsy in PI-RADS 5 patients: a multivariate analysis of clinical and imaging-based factors.

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications.

Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial

Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer: a population-based study.

Fear of Cancer Recurrence among Uninsured and Underrepresented Men with Prostate Cancer.

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.

A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules.

Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy.

Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.

Patterns of prostate recurrence after focal salvage prostate brachytherapy for radiorecurrent prostate cancer.

Salvage stereotactic MR-Guided adaptive radiotherapy (SMART) re-irradiation for locally recurrent prostate Cancer: Clinical and dosimetric outcomes.

Evaluation of hybrid DIR performance using controlling structures and points of interest in MR-guided adaptive radiotherapy for prostate cancer patients.

Prostate Cancer-Related Genetic Counseling in a Safety-Net Healthcare Setting - Beyond the Abstract

Prostate Cancer Screening in Transgender Women/Transfeminine Persons: Building on Canadian Evidence - Beyond the Abstract

Artificial Intelligence Defines Spatial Patterns of Tumor-Infiltrating Lymphocytes Highly Associated with Outcome - a Pan-GI Cancer Study - Beyond the Abstract

Deep Learning-Based PSMA PET Segmentation Repeatability: A Post-Hoc Analysis of a Single-Center, Prospective, Test-Retest Trial - Beyond the Abstract

Upper Tract Tumors

Renal function decline after radical nephroureterectomy: Longitudinal analysis and predictive factors in upper tract urothelial carcinoma.

Current Knowledge on UTUC Epidemiology in Poland Compared to Europe.

Testicular Cancer

Cryopreservation of Spermatozoa Prior and Post-Orchiectomy in Patients With Testicular Germ Cell Cancer-Does the Timing Matter?

Risk-adapted management in stage I testicular germ-cell tumors: long-term outcomes from a single-center cohort (1994-2023).

Stigma experiences among young and middle-aged testicular cancer survivors in China: A phenomenological study.

Zip Code, Race, and Ethnicity: The Impact of Socioeconomic Hardship on Cancer Presentation and Survival Among Patients with Testicular Germ Cell Tumors - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC